Results 141 to 150 of about 70,208 (264)

Feasibility and Safety of Venetoclax for Cytoreduction During Induction Therapy in Newly Diagnosed Acute Promyelocytic Leukemia

European Journal of Haematology, EarlyView.
ABSTRACT Objective This study aimed to evaluate the feasibility and safety of venetoclax as a cytoreductive strategy during induction therapy in newly diagnosed acute promyelocytic leukemia (APL), and to provide an exploratory description of its early efficacy.
Yu Wang, Rong Xiao, Xiaobing Huang, Yi Xiao   +3 more
wiley   +1 more source

Griffithsin-mediated inhibition of cellular entry of hemorrhagic fever viruses and insights into its mechanisms. [PDF]

J Virol
Saito T, Furuyama W, Muthusinghe DS, Munyeku-Bazitama Y, Hattori T, Okabe M, Yokoyama T, Tanaka Y, Sakai R, Sakurai Y, Sakaguchi M, Tsukagoshi R, Coronado Barrios NS, Tipih T, Rosenke K, Marzi A, Igarashi M, Urata S, Maruyama J, Nanbo A, Takada A.   +20 more
europepmc   +1 more source

Prospective Study of Targeted Busulfan–Fludarabine Conditioning for Hematopoietic Stem Cell Transplantation in Genetic Rare Diseases

European Journal of Haematology, EarlyView.
ABSTRACT Objectives Genetic rare diseases (GRDs), including chronic granulomatous disease, familial hemophagocytic lymphohistiocytosis, and congenital neutropenia, often require hematopoietic stem cell transplantation (HSCT) as the only curative option.
Bo Kyung Kim, Kyung Taek Hong, Jung Yoon Choi, Hyun Jin Park, Kyung‐Sang Yu, In‐Jin Jang, Hyoung Jin Kang   +6 more
wiley   +1 more source

Multiple Reassortments, Limited Geographic Spread, and Comparable Pathogenicity of Crimean-Congo Hemorrhagic Fever Viruses in Sivas Province, Türkiye. [PDF]

J Med Virol
Lin Q, Elaldi N, Yigit M, Yildiz B, Hewson R, López-García M, Lythe G, Pektas AN, Koksal B, Tasseten TN, Deniz A, Bedir H, Kiymaz YC, Vatansever Z, Molina-París C, Leitner T.   +15 more
europepmc   +1 more source

Italian Patients Journey for Gene Therapy in Haemophilia A

Haemophilia, EarlyView.
ABSTRACT Introduction Gene therapy (GT) provides sustained FVIII levels without repeated infusions in Hemophilia A (HA) patients thus overcoming a major limitation of replacement therapy. However, issues remain e.g., patient selection criteria, duration and variability of transgene expression, quality of life and long‐term safety.
Giovanni Di Minno, Gaia Spadarella, Alessandra Borchiellini, Anna Borrelli, Andrea Buzzi, Giancarlo Castaman, Michele Cecchi, Raimondo De Cristofaro, Vincenzo La Mura, Angelo Lupi, Giuseppe Malcangi, Maria Elisa Mancuso, Maria Francesca Mansueto, Cristina Santoro, Rita Carlotta Santoro, Luigi Piero Solimeno, Annarita Tagliaferri, Ezio Zanon, Isabella Garagiola, Flora Peyvandi   +19 more
wiley   +1 more source

Potential Mechanisms Underlying Bleeding During Infection With Hemorrhagic Fever Viruses. [PDF]

Arterioscler Thromb Vasc Biol
Perkins MV, Mackman N.
europepmc   +1 more source

Beyond the Kidney and Lung: Cutaneous and Mucosal Clues to Human Hantavirus Disease

International Journal of Dermatology, EarlyView.
Rodent exposure and aerosolized excreta can lead to hantavirus infection with systemic endothelial injury and capillary leak, resulting in thrombocytopenia and syndromes such as HPS/HCPS and HFRS/NE. Early dermatologic and mucosal findings, including flushing, conjunctival injection, petechiae/purpura, and mucosal bleeding, may provide important clues ...
Giuseppe Gallo, Pietro Quaglino, Simone Ribero   +2 more
wiley   +1 more source

Prognostic Value of Admission Glucose and Extended Lipid Profile in Patients with Crimean-Congo Hemorrhagic Fever. [PDF]

J Med Virol
Kıymaz YÇ, Baysal C, Öksüz C, Büyüktuna SA, Elaldı N.   +4 more
europepmc   +1 more source

Management of Non‐Plaque‐Induced Gingival Conditions: A Systematic Review—Part 2: Inflammatory and Immune Conditions; Neoplasms; and Gingival Pigmentation

Journal of Clinical Periodontology, EarlyView.
ABSTRACT Aims This systematic review assesses current evidence on the management of non‐plaque (dental biofilm)‐induced gingival diseases and conditions (NPIGDs), including (i) inflammatory and immune conditions, (ii) neoplasms and (iii) gingival pigmentations.
Maria Clotilde Carra, Cecile Wasielewski, Bruno Špiljak, Maja Sabalić‐Schoener, Sebastien Jungo, Ivan Alajbeg   +5 more
wiley   +1 more source

A randomized phase 2 trial of socrodeucitinib in moderate‐to‐severe plaque psoriasis

Journal of the European Academy of Dermatology and Venereology, EarlyView.
In moderate‐to‐severe plaque psoriasis, socrodeucitinib (6 mg/12 mg) significantly outperformed placebo at week 12: PASI 75 response rates 28.6%/72.1% vs. 7.5%. Meanwhile, socrodeucitinib illustrated a favourable safety and tolerability profile, warranting further study.
Ling Han, Songmei Geng, Yangfeng Ding, Shifa Zhang, Xiaohua Wang, Fengming Hu, Jianguo Li, Chao Ci, Yayu Hu, Rixin Chen, Jianping Zhang, Xiaoyong Zhou, Aijun Chen, Chunlei Zhang, Tiechi Lei, Yanyan Feng, Yu Wang, Zudong Meng, Yan Zhou, Mingkai Ji, Wei Liu, Yunting Wu, Qianying Chen, Siyi Wang, Jinhua Xu   +24 more
wiley   +1 more source